Opdualag (nivo + relatlimab)

About Ono Pharmaceutical

Ono Pharmaceutical's mission is to address unmet medical needs through the discovery and development of first-in-class and best-in-class therapeutic agents. The company has achieved global recognition primarily through its strategic alliance with Bristol Myers Squibb on the blockbuster PD-1 inhibitor Opdivo (nivolumab), which established its strong foothold in immuno-oncology. Its strategy centers on sustained internal R&D investment, complemented by strategic partnerships and in-licensing to expand its pipeline and global commercial reach. Ono is now executing a multi-faceted growth plan to diversify its portfolio beyond Opdivo and solidify its position as a global specialty pharma leader.

Therapeutic Areas

Other Metastatic Melanoma Drugs